T1	Participants 69 120	218 patients with a median follow-up of eight years
T2	Participants 276 407	patients with advanced stage Hodgkin's disease (HD), as well as in early stage patients with systemic symptoms and/or bulky disease
T3	Participants 428 469	218 patients with previously untreated HD
T4	Participants 1105 1143	patients who entered the ABVD/MOPP arm
